Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 6/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.31 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132631 | 0.85 | KLK7 (0.33) | KLK7KLK5PLA2G10PLA2G5KDM4E | |
| SCHEMBL2132635 | 0.85 | KLK7 (0.33) | KLK7KLK5PLA2G10PLA2G5KDM4E | |
| SCHEMBL7132129 | 0.76 | KLK7 (0.36) | KLK7KLK5NR1H2PRSS1PRSS2 | |
| SCHEMBL3324495 | 0.76 | KLK7 (0.36) | KLK7KLK5NR1H2PRSS1PRSS2 | |
| SCHEMBL12570509 | 0.74 | KLK7 (0.32) | KLK7KLK5 | |
| SCHEMBL7609856 | 0.74 | USP2 (0.35) | KLK7NR1H2KDM4EMAPTTHRB | |
| SCHEMBL8886176 | 0.69 | GLA (0.39) | KLK7KLK5NR1H3NR1H2PRSS1 | |
| SCHEMBL5891823 | 0.69 | GLA (0.39) | KLK7KLK5NR1H3NR1H2PRSS1 | |
| SCHEMBL8886431 | 0.68 | NR1H3 (0.36) | KLK7KLK5NR1H3NR1H2PRSS1 | |
| SCHEMBL8073190 | 0.68 | NR1H3 (0.36) | KLK7KLK5NR1H3NR1H2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125073-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125073-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BCOR, BRDT, TPMT | KLK7 4474/4885KLK5 3596/4885NR1H3 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.